What are the key differences between Tirzepatide and Semaglutide for weight loss?

Tirzepatide is a dual GLP-1 and GIP receptor agonist, while Semaglutide primarily acts as a GLP-1 agonist. Clinical trials show Tirzepatide achieves greater average body weight loss (up to 22.5%) compared to Semaglutide (15-20%) due to its multifaceted mechanism. While both are highly effective, Semaglutide currently boasts more extensive long-term safety data as the 'most proven' option.

How does AOD-9604 contribute to fat loss and body recomposition without typical GLP-1 side effects?

AOD-9604 is a modified fragment of human growth hormone that specifically stimulates fat metabolism (lipolysis) and inhibits the formation of new fat (lipogenesis), primarily targeting adipose tissue. Unlike GLP-1 agonists, it does not influence appetite suppression or gastric emptying, which accounts for its characteristic 'no GI sides'. It's often used in combination with GH secretagogues like CJC-1295/Ipamorelin to support fat loss while preserving lean muscle mass during body recomposition.

Which peptides are most effective for targeting stubborn belly fat, particularly visceral fat?

Tesamorelin is specifically noted for its efficacy in reducing visceral adipose tissue (VAT), with clinical trials demonstrating an average reduction of 18% in VAT. While not a primary weight loss peptide, it directly targets deep belly fat. For enhanced results in localized fat reduction, it can be combined with AOD-9604, which further aids in fat metabolism.

Why is baseline blood work recommended before starting a metabolic weight loss peptide protocol?

Establishing baseline blood work, including fasting insulin, HbA1c, a lipid panel, and a thyroid panel, is crucial for two primary reasons. Firstly, it allows you to accurately track and quantify the real metabolic improvements achieved by the peptides over time. Secondly, it helps identify any pre-existing conditions or contraindications, such as a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), ensuring the safest and most effective protocol.

What is PeptideKey's PRISM ranking system for evaluating weight loss peptides?

The PRISM ranking system is PeptideKey.com's proprietary, evidence-based methodology designed to evaluate and rank peptides for metabolic weight management. This system rigorously assesses factors such as clinical trial data (Phase 2/3), demonstrated efficacy (e.g., percentage of body weight loss), safety profiles, and mechanisms of action. It provides researchers and buyers with a clear, data-driven framework for comparing and selecting the most promising options like Retatrutide, Tirzepatide, and Semaglutide.

PeptideKey

Metabolic Weight: Tirzepatide vs Semaglutide—The Data

Manage metabolic health & weight with peptides. Our 2026 buying guide provides clear criteria, safety considerations, and research checklists for informed choices.

This page is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.